US biotechnology firm Regeneron Pharmaceuticals has lost its opposition to a proposed patent by UK biopharmaceutical company Kymab for a method of producing an animal with part-human DNA.
A six-week trial set to start in October in the cartel case against mobility equipment provider Country Care Group has been vacated and rescheduled to next year, as the judge overseeing the case quipped that he was either the “canary or the guinea pig” in the landmark criminal proceeding.
Korean drug company Samsung Bioepis has filed a lawsuit seeking to invalidate German drug company Fresenius Kadi’s patent for a biosimilar of blockbuster arthritis drug Humira.
A judge has ordered a leading doctor’s professional body to hand over its member list to the applicants in the Ethicon pelvic mesh class action, after the organisation tried to argue its physical member book didn’t strictly fall within the terms of a court order.
Mylan and Cipla have reached a speedy resolution of a consumer lawsuit accusing Cipla of copying the get-up of Mylan’s blockbuster cholesterol drug Lipidil.
A judge has slapped a $10 million fine on online supplement company Peptide Clinics for advertising prescription-only drugs in breach of the Therapeutic Goods Act.
Mylan has launched a lawsuit against Cipla for allegedly copying the get-up of its blockbuster cholesterol drug Lipidil, after losing a bid to block Cipla and Sun Pharma from selling generic versions of the drug while it appeals a ruling invalidating several claims of its patents.
A unit of Boehringer Ingelheim has been given more time to oppose a proposed patent by rival drug maker Intervet, after the German drug company’s lawyers sent an email with the wrong opposition deadline.
An application by the former boss of Sirtex Medical for a sentencing date in the insider trading case against him has raised the ire of a NSW District Court judge, who called the bid premature and an attempt to jump the queue.
Residential aged care provider Estia Health says it will “vigorously defend” a class action filed by Phi Finney McDonald on behalf of shareholders who allege the company failed to disclose serious commercial difficulties with its acquisition strategy.